How to buy Lumos Pharma stock | $9.04

Lumos Pharma Inc is a biotechnology business based in the US. Lumos Pharma shares (LUMO) are listed on the NASDAQ and all prices are listed in US Dollars. Lumos Pharma employs 27 staff and has a trailing 12-month revenue of around 0.00.

Lumos Pharma stock price (NASDAQ: LUMO)

Use our graph to track the performance of LUMO stocks over time.

Lumos Pharma shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$9.04
52-week range	$7.23 - $36.72
50-day moving average	$9.91
200-day moving average	$10.11
Wall St. target price	$27.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.16

Buy Lumos Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Lumos Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lumos Pharma price performance over time

Historical closes compared with the close of $9.04 from 2021-10-22

1 week (2021-10-15)	-2.27%
1 month (2021-09-24)	-11.02%
3 months (2021-07-23)	17.56%
6 months (2021-04-23)	-32.74%

1 year (2020-10-23)	-37.22%
2 years (2019-10-24)	465.00%
3 years (2018-10-24)	356.57%
5 years (2016-10-24)	14.15

Lumos Pharma financials

Revenue TTM	$123,000
Gross profit TTM	$168,000
Return on assets TTM	-13.44%
Return on equity TTM	-16.5%
Profit margin	0%
Book value	$12.10
Market capitalisation	$75.6 million

TTM: trailing 12 months

Shorting Lumos Pharma shares

There are currently 85,895 Lumos Pharma shares held short by investors – that's known as Lumos Pharma's "short interest". This figure is 12% down from 97,557 last month.

There are a few different ways that this level of interest in shorting Lumos Pharma shares can be evaluated.

Lumos Pharma's "short interest ratio" (SIR)

Lumos Pharma's "short interest ratio" (SIR) is the quantity of Lumos Pharma shares currently shorted divided by the average quantity of Lumos Pharma shares traded daily (recently around 26267.584097859). Lumos Pharma's SIR currently stands at 3.27. In other words for every 100,000 Lumos Pharma shares traded daily on the market, roughly 3270 shares are currently held short.

However Lumos Pharma's short interest can also be evaluated against the total number of Lumos Pharma shares, or, against the total number of tradable Lumos Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lumos Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Lumos Pharma shares in existence, roughly 10 shares are currently held short) or 0.0136% of the tradable shares (for every 100,000 tradable Lumos Pharma shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lumos Pharma.

Find out more about how you can short Lumos Pharma stock.

Lumos Pharma share dividends

We're not expecting Lumos Pharma to pay a dividend over the next 12 months.

Have Lumos Pharma's shares ever split?

Lumos Pharma's shares were split on a 1:9 basis on 18 March 2020. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lumos Pharma shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Lumos Pharma shares which in turn could have impacted Lumos Pharma's share price.

Lumos Pharma overview

Lumos Pharma, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas. .

Frequently asked questions

What percentage of Lumos Pharma is owned by insiders or institutions?
Currently 28.506% of Lumos Pharma shares are held by insiders and 38.639% by institutions. How many people work for Lumos Pharma?
Latest data suggests 27 work at Lumos Pharma. When does the fiscal year end for Lumos Pharma?
Lumos Pharma's fiscal year ends in December. Where is Lumos Pharma based?
Lumos Pharma's address is: 4200 Marathon Boulevard, Austin, TX, United States, 78756 What is Lumos Pharma's ISIN number?
Lumos Pharma's international securities identification number is: US55028X1090 What is Lumos Pharma's CUSIP number?
Lumos Pharma's Committee on Uniform Securities Identification Procedures number is: 55028X109